Aeglea BioTherapeutics Market Cap 2011-2026 | AGLE

As of March 24, 2026 Aeglea BioTherapeutics has a market cap of $ 1.01 B

Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.^[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Aeglea BioTherapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	724 M	433 M	1.35 M	12.5 M	420 M	226 M	187 M	104 M	39.3 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
724 M	1.35 M	239 M

References

Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer	Market Cap	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	315 M	-	2.43 %	$ 254 M	Germany
Heron Therapeutics HRTX	198 M	$ 0.8	2.7 %	$ 133 M	USA
Amphastar Pharmaceuticals AMPH	1.25 B	$ 19.23	-1.38 %	$ 899 M	USA
Altimmune ALT	318 M	$ 3.44	2.99 %	$ 303 M	USA
Aytu BioScience AYTU	15.8 M	$ 2.63	0.77 %	$ 16.5 M	USA
I-Mab IMAB	127 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	33.6 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	168 B	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	549 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	7.37 B	$ 218.06	-1.72 %	$ 5 B	Danmark
Midatech Pharma plc MTP	79 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	28.9 M	-	-1.52 %	$ 24.7 M	USA
Incyte Corporation INCY	19.5 B	$ 90.45	-0.36 %	$ 17.7 B	USA
Applied Genetic Technologies Corporation AGTC	32.8 M	-	-	$ 26.5 M	USA
Inovio Pharmaceuticals INO	220 M	$ 1.61	1.9 %	$ 35.7 M	USA
ARCA biopharma ABIO	484 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	41.4 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	14.1 K	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	16.7 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	538 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	38.2 M	-	10.36 %	$ 9.8 M	USA
Acasti Pharma ACST	40.7 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	2.83 B	-	-	-	Russia
Inventiva S.A. IVA	535 M	$ 6.08	5.19 %	$ 138 M	France
Avenue Therapeutics ATXI	544 K	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	76.4 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	12.1 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	1.87 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	7.72 M	-	-	$ 7.46 M	Israel
Cullinan Management CGEM	898 M	$ 12.84	0.78 %	$ 774 M	USA
Atreca BCEL	49 M	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	308 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	253 B	-	0.49 %	$ 251 B	Cayman-islands
KalVista Pharmaceuticals KALV	770 M	$ 16.6	-2.35 %	$ 824 M	Britain
Kamada Ltd. KMDA	271 M	$ 8.2	-0.61 %	$ 260 M	Israel
Calithera Biosciences CALA	960 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	54.1 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	1.82 M	-	-	$ 3.74 B	USA
Bellerophon Therapeutics BLPH	78.6 M	-	-74.18 %	$ 955 K	USA
Karyopharm Therapeutics KPTI	73.1 K	$ 6.66	-12.71 %	$ 812 K	USA
Keros Therapeutics KROS	513 M	$ 11.24	2.55 %	$ 418 M	USA
Checkpoint Therapeutics CKPT	160 M	-	-	$ 169 M	USA
Clovis Oncology CLVS	231 M	-	-7.23 %	$ 13 M	USA
CureVac N.V. CVAC	3.53 B	-	-	$ 867 M	Germany
Longeveron LGVN	16.9 B	$ 0.95	-2.71 %	$ 16.7 B	USA
Denali Therapeutics DNLI	3.04 B	$ 21.09	4.56 %	$ 3.47 B	USA
Akero Therapeutics AKRO	3.25 B	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	445 M	$ 4.42	4.25 %	$ 734 M	Canada
Akouos AKUS	172 M	-	0.23 %	$ 488 M	USA